• Facets (new session)
• Description
• Metadata
• Settings
  • Rule: ActivityStreamsMapasEquivalentb3sb3sifpdbprdf-labelfacetshttp://dbpedia.org/resource/inference/rules/dbpedia#http://dbpedia.org/resource/inference/rules/opencyc#http://dbpedia.org/resource/inference/rules/umbel#http://dbpedia.org/resource/inference/rules/yago#http://dbpedia.org/schema/property_rules#http://www.ontologyportal.org/inference/rules/SUMO#http://www.ontologyportal.org/inference/rules/WordNet#http://www.w3.org/2002/07/owl#ldpoplwebskos-transurn:det:rdf:labelvirtrdf-labelvirtrdf-urlNone
    
  • Inverse Functional Properties: Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects
  • "Same As": Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects (recommended) Apply to subjects, objects and predicates (not recommended on big datasets) Apply to predicates only (special use cases only)

About: dbr:Aliskiren     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : umbel-rc:DrugProduct, within Data Space : dbpedia.demo.openlinksw.com associated with source document(s)

Type: Thingdul:ChemicalObjectchemical substanceDrugyago:WikicatAmidesyago:WikicatAminesyago:WikicatMolecularFormulasyago:Abstraction100002137yago:Agent114778436yago:Alcohol107884567yago:AliphaticCompound114601294yago:Amide114724264yago:Amine114739004yago:Beverage107881800yago:CausalAgent100007347yago:Chemical114806838yago:Communication100033020yago:Compound114818238yago:Drug103247620yago:DrugOfAbuse103248958yago:Element114840755yago:Fluid114939900yago:Food100021265yago:Formula106816935yago:Liquid114940386yago:Material114580897yago:Matter100020827yago:Message106598915yago:MethaneSeries114951377yago:MolecularFormula106817173yago:OrganicCompound114727670yago:Part113809207yago:PhysicalEntity100001930yago:Quintessence114847103yago:Relation100031921drugyago:Statement106722453yago:Substance100019613yago:Substance100020090yago:WikicatAlcoholsyago:WikicatEthersyago:WikicatPhenolEthersumbel-rc:DrugProduct New Facet based on Instances of this Class

Aliskiren (brand names Tekturna and Rasilez) is the first in a class of drugs called direct renin inhibitors. It is used for essential (primary) hypertension. While used for high blood pressure, other better studied medications are typically recommended due to concerns of higher side effects and less evidence of benefit. In December 2011, Novartis halted a trial of the drug after discovering increased nonfatal stroke, kidney complications, high blood potassium, and low blood pressure in people with diabetes and kidney problems. As a result, in 2012: